imatinib mesylate has been researched along with Metabolic Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kadowaki, T; Kubota, N | 1 |
1 other study(ies) available for imatinib mesylate and Metabolic Syndrome
| Article | Year |
|---|---|
Protective role of imatinib in atherosclerosis.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Benzamides; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Humans; Imatinib Mesylate; Insulin Resistance; Metabolic Syndrome; Mice; Mice, Knockout; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Risk Factors | 2004 |